← Back to Search

Other

VK2735 for Obesity (VENTURE Trial)

Phase 2
Waitlist Available
Research Sponsored by Viking Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years of age at the time of signing the informed consent
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 13 weeks
Awards & highlights

VENTURE Trial Summary

This trial will assess a drug that may help obese/overweight adults lose weight and improve related conditions. It will be tested in a 13-week, double-blind, placebo-controlled study.

Who is the study for?
This trial is for adults over 18 with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition, but not heavier than a BMI of 50. It's not for those who've had significant weight changes recently, have diabetes or chronic pancreatitis, used certain drugs for weight loss in the past 6 months, or have specific medical conditions that could affect their participation.Check my eligibility
What is being tested?
The study tests VK2735 against a placebo to see if it's safe and effective for weight loss. Participants will be randomly assigned to receive either VK2735 or a placebo once weekly for 13 weeks while researchers track safety, how well it works, and how the body processes the drug.See study design
What are the potential side effects?
While the side effects are not detailed here, common issues with medications like VK2735 may include digestive discomforts such as nausea or constipation, potential allergic reactions, headaches and possibly injection site reactions since it's administered weekly.

VENTURE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

VENTURE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~13 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 13 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent (relative) change from baseline to Week 13 in body weight
Secondary outcome measures
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
Other outcome measures
Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI

VENTURE Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: VK2735 (Dose #4)Experimental Treatment1 Intervention
VK2735 is a peptide GLP-1 and GIP dual agonist
Group II: VK2735 (Dose #3)Experimental Treatment1 Intervention
VK2735 is a peptide GLP-1 and GIP dual agonist
Group III: VK2735 (Dose #2)Experimental Treatment1 Intervention
VK2735 is a peptide GLP-1 and GIP dual agonist
Group IV: VK2735 (Dose #1)Experimental Treatment1 Intervention
VK2735 is a peptide GLP-1 and GIP dual agonist
Group V: VK2735 (Placebo)Placebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Viking Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
587 Total Patients Enrolled
1 Trials studying Weight Loss
136 Patients Enrolled for Weight Loss

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new volunteers currently being accepted for this trial?

"This clinical trial has been posted to clinicaltrials.gov and is actively seeking candidates since August 31, 2023; with the most recent edit on September 28th of that same year."

Answered by AI

What is the upper cap of people participating in this clinical study?

"To facilitate this trial, 125 qualified individuals are required. These participants can be recruited from two University-affiliated medical centres – Viking Clinical Site #114 in Long Beach and Viking Clinical Site #110 in Los Angeles."

Answered by AI

Has VK2735 (Dose #1) received federal endorsement yet?

"Our team at Power has assigned VK2735 (Dose #1) a score of 2 out of 3 based on Phase 2 trial data that suggests there is some safety backing, but no efficacy evidence."

Answered by AI

How many healthcare centers are conducting this trial?

"The clinical trial is hosted in multiple locations throughout the United States, including Viking Clinical Site #114 located in Long Beach, California; Viking Clinical Site #110 based out of Los Angeles, Florida; and Viking Clinical Site #113 situated in Tustin, Indiana. There are 20 other recruiting sites as well."

Answered by AI

Who else is applying?

What site did they apply to?
Viking Clinical Site #119
Viking Clinical Site #110
Viking Clinical Site #100
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

What questions have other patients asked about this trial?

How soon can start? How long does it take? How long does it take per screening?
PatientReceived 2+ prior treatments
I noticed at the top of this application it stated Placebo. Is there a chance you do not get to experience the effects of a new drug?
PatientReceived 2+ prior treatments

Why did patients apply to this trial?

Over weight my whole life. Interested in losing weight. I’ve tried 4 times to loose weight.
PatientReceived 2+ prior treatments
Roller coaster dieting since age 20. I’ve tried another drug that didn’t work.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
Average response time
  • < 1 Day
Most responsive sites:
  1. Viking Clinical Site #103: < 24 hours
Recent research and studies
clinicaltrials.govStudy
VK2735 for Weight Management Phase 2
2023. "VK2735 for Weight Management Phase 2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06068946.
All > Weight Loss Glendale > Knoxville
~106 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top